Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Approaches to drug therapy for COPD in Russia: a proposed therapeutic algorithm.

Zykov KA, Ovcharenko SI.

Int J Chron Obstruct Pulmon Dis. 2017 Apr 11;12:1125-1133. doi: 10.2147/COPD.S125594. eCollection 2017.

2.

Early detection of COPD patients in GOLD 0 population: an observational non-interventional cohort study - MARKO study.

Vrbica Ž, Labor M, Gudelj I, Labor S, Jurić I, Plavec D; MARKO study group..

BMC Pulm Med. 2017 Feb 10;17(1):36. doi: 10.1186/s12890-017-0378-6.

3.

Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD.

Calverley PM, Eriksson G, Jenkins CR, Anzueto AR, Make BJ, Persson A, Fagerås M, Postma DS.

Int J Chron Obstruct Pulmon Dis. 2016 Dec 19;12:13-25. doi: 10.2147/COPD.S114209. eCollection 2017.

4.

Active case finding strategy for chronic obstructive pulmonary disease with handheld spirometry.

Kim JK, Lee CM, Park JY, Kim JH, Park SH, Jang SH, Jung KS, Yoo KH, Park YB, Rhee CK, Kim DK, Hwang YI.

Medicine (Baltimore). 2016 Dec;95(50):e5683.

5.

The impact of olodaterol on the risk of mortality and serious adverse events: a systematic review and meta-analysis.

Lee HW, Kim HJ, Lee CH.

Br J Clin Pharmacol. 2017 Jun;83(6):1166-1175. doi: 10.1111/bcp.13210. Epub 2017 Jan 12.

PMID:
27957746
6.
7.

Exacerbations in the pre- and post-COPD diagnosis periods.

Yawn BP, Wollan P, Rank M.

Pragmat Obs Res. 2013 Apr 30;4:1-6. eCollection 2013.

8.

Comorbidity as a contributor to frequent severe acute exacerbation in COPD patients.

Jeong SH, Lee H, Carriere KC, Shin SH, Moon SM, Jeong BH, Koh WJ, Park HY.

Int J Chron Obstruct Pulmon Dis. 2016 Aug 4;11:1857-65. doi: 10.2147/COPD.S103063. eCollection 2016.

9.

Individualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management?

Stockley RA, Edgar RG, Pillai A, Turner AM.

Int J Chron Obstruct Pulmon Dis. 2016 Aug 1;11:1745-56. doi: 10.2147/COPD.S111508. eCollection 2016.

10.

Strategies for Management of the Early Chronic Obstructive Lung Disease.

Lee JY, Rhee CK, Jung KS, Yoo KH.

Tuberc Respir Dis (Seoul). 2016 Jul;79(3):121-6. doi: 10.4046/trd.2016.79.3.121. Epub 2016 Jul 1. Review.

11.

Efficacy and safety of conventional long acting β2- agonists: systematic review and meta-analysis.

Karbasi-Afshar R, Aslani J, Ghanei M.

Caspian J Intern Med. 2016 Spring;7(2):64-70. Review.

12.

Predictors of Hospitalized Exacerbations and Mortality in Chronic Obstructive Pulmonary Disease.

Santibáñez M, Garrastazu R, Ruiz-Nuñez M, Helguera JM, Arenal S, Bonnardeux C, León C, García-Rivero JL.

PLoS One. 2016 Jun 30;11(6):e0158727. doi: 10.1371/journal.pone.0158727. eCollection 2016.

13.

Prompt initiation of maintenance treatment following a COPD exacerbation: outcomes in a large insured population.

Coutinho AD, Lokhandwala T, Boggs RL, Dalal AA, Landsman-Blumberg PB, Priest J, Stempel DA.

Int J Chron Obstruct Pulmon Dis. 2016 Jun 8;11:1223-31. doi: 10.2147/COPD.S102570. eCollection 2016.

14.

Impacts of coexisting bronchial asthma on severe exacerbations in mild-to-moderate COPD: results from a national database.

Lee H, Rhee CK, Lee BJ, Choi DC, Kim JA, Kim SH, Jeong Y, Kim TH, Chon GR, Jung KS, Lee SH, Price D, Yoo KH, Park HY.

Int J Chron Obstruct Pulmon Dis. 2016 Apr 15;11:775-83. doi: 10.2147/COPD.S95954. eCollection 2016.

15.

Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations.

Calverley PM, Postma DS, Anzueto AR, Make BJ, Eriksson G, Peterson S, Jenkins CR.

Int J Chron Obstruct Pulmon Dis. 2016 Feb 25;11:381-90. doi: 10.2147/COPD.S93303. eCollection 2016.

16.

Age-related annual decline of lung function in patients with COPD.

Kim SJ, Lee J, Park YS, Lee CH, Yoon HI, Lee SM, Yim JJ, Kim YW, Han SK, Yoo CG.

Int J Chron Obstruct Pulmon Dis. 2015 Dec 30;11:51-60. doi: 10.2147/COPD.S95028. eCollection 2016.

17.

COPD: it is time to change!

Tantucci C, Pini L.

Int J Chron Obstruct Pulmon Dis. 2015 Nov 11;10:2451-7. doi: 10.2147/COPD.S87696. eCollection 2015.

18.

The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD.

Papi A, Jones PW, Dalvi PS, McAulay K, McIver T, Dissanayake S.

Int J Chron Obstruct Pulmon Dis. 2015 Nov 9;10:2431-8. doi: 10.2147/COPD.S93375. eCollection 2015.

19.

Pharmacological treatment response according to the severity of symptoms in patients with chronic obstructive pulmonary disease.

Lee JS, Seo JB, Lee SM, Park TS, Lee SW, Oh YM, Lee JH, Kim EK, Kim TH, Park JH, Sheen SS, Lim SY, Jung I, Lee SD.

J Thorac Dis. 2015 Oct;7(10):1765-73. doi: 10.3978/j.issn.2072-1439.2015.10.27.

20.

Comparative effectiveness of budesonide/formoterol combination and tiotropium bromide among COPD patients new to these controller treatments.

Trudo F, Kern DM, Davis JR, Tunceli O, Zhou S, Graham EL, Strange C, Williams SA.

Int J Chron Obstruct Pulmon Dis. 2015 Sep 28;10:2055-66. doi: 10.2147/COPD.S90658. eCollection 2015.

Supplemental Content

Support Center